IPO - 60 DEGREES PHARMACEUTICALS, INC.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: Update

Accession Number: 000101376225003353

Filing Summary: 60 Degrees Pharmaceuticals, Inc. has filed an amended registration statement under the Securities Act of 1933 on March 27, 2025, indicating its intention to offer and sell up to 747,200 shares of its common stock. This filing includes a detailed prospectus related to the resale of common stock by selling stockholders, which includes 408,621 shares from January 2025 Common Warrants and 300,700 shares from February 2025 Warrants, among others. The document outlines the terms under which the shares may be sold, including pricing, the nature of the securities involved, and the responsibilities of both the company and the selling stockholders. The company also notes its status as an emerging growth and smaller reporting company, thereby complying with reduced public company reporting requirements. Furthermore, it elaborates on its primary product, Arakoda, approved for malaria prevention, and mentions ongoing development for additional therapeutic indications, particularly in infectious diseases. The document emphasizes that the registration statement's effectiveness is pending, highlighting risks and market opportunities associated with the company's products. Overall, this filing represents a significant step in the company's efforts to raise capital and expand its business initiatives.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-02-14

Corporate Action: Ipo

Type: New

Accession Number: 000121390025014334

Filing Summary: 60 Degrees Pharmaceuticals, Inc. filed a registration statement on Form S-1 with the United States Securities and Exchange Commission on February 14, 2025. The filing indicates the intention to conduct a public offering of up to 3,735,977 shares of common stock at a par value of $0.0001 per share. The common stock is being offered by selling stockholders, and the registration includes shares issuable upon the exercise of various warrants acquired in recent private placements. Key details include: 2,043,098 shares from January 2025 Common Warrants at an exercise price of $0.771, and 1,503,500 shares from February 2025 Common Warrants at $0.59. The registration statement is filed pursuant to the Securities Act of 1933, with the aim of immediately reselling the shares once the registration is effective. The company has stated it will not receive any proceeds from the sale of shares by selling stockholders, but it anticipates receiving approximately $1.5 million from exercise of the warrants by the selling stockholders. The company is categorized as a smaller reporting and emerging growth company under the JOBS Act. The prospectus highlights growth opportunities in the malaria prevention market and positions the company for potential future treatments for tick-borne and fungal diseases, leveraging existing products and research in development.

Document Link: View Document